

=> d his

(FILE 'HOME' ENTERED AT 13:05:00 ON 01 NOV 2001)

FILE 'MEDLINE' ENTERED AT 13:05:06 ON 01 NOV 2001

L1	4797 S PARAINFLUENZA
L2	211 S PARAINFLUENZA TYPE 3
L3	0 S CHIEMRIC
L4	17374 S CHIMERIC
L5	2 S L2 AND L4
L6	30 S BOVINE PARAINFLUENZA VIRUS TYPE 3
L7	5 S L4 AND L6

FILE 'USPATFULL' ENTERED AT 13:09:40 ON 01 NOV 2001

L8	10 S L7
L9	0 S L8/CLM

d 18 1-10

L8 ANSWER 1 OF 10 USPATFULL  
AN 2001:18001 USPATFULL  
TI Recombinant **chimeric** virus and uses thereof  
IN Cochran, Mark D., Carlsbad, CA, United States  
Wild, Martha A., San Diego, CA, United States  
Winslow, Barbara J., Delmar, CA, United States  
PA Schering-Plough Veterinary Corp., Reno, NV, United States (U.S.  
corporation)  
PI US 6183753 B1 20010206  
AI US 1997-804372 19970221 (8)  
RLI Continuation-in-part of Ser. No. US 1996-663566, filed on 13 Jun 1996,  
now patented, Pat. No. US 5853733 Continuation-in-part of Ser. No. WO  
1995-US10245, filed on 9 Aug 1995 Continuation-in-part of Ser. No. US  
1994-288065, filed on 9 Aug 1994, now patented, Pat. No. US 5961982  
DT Utility  
FS Granted  
LN.CNT 3184  
INCL INCLM: 424/199.100  
INCLS: 424/229.100; 424/204.100; 424/222.100; 424/202.100; 435/320.100;  
435/069.100; 435/069.300; 435/235.100; 536/023.720; 536/023.520  
NCL NCLM: 424/199.100  
NCLS: 424/202.100; 424/204.100; 424/222.100; 424/229.100; 435/069.100;  
435/069.300; 435/235.100; 435/320.100; 536/023.520; 536/023.720  
IC [7]  
ICM: A61K039-12  
ICS: A61K039-295; C12N015-00; C12P021-06  
EXF 424/199.1; 424/202.1; 424/204.1; 424/222.1; 424/816; 424/229.1;  
435/320.1; 435/69.1; 435/235.1; 435/177.3; 530/300; 530/350; 536/23.72;  
536/23.52  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 10 USPATFULL  
AN 2001:14256 USPATFULL  
TI Two-step immunization procedure against the pyramyxoviridae family of  
viruses using recombinant virus and subunit protein preparation  
IN Klein, Michel H., Willowdale, Canada  
Tartaglia, James, Schenectady, NY, United States  
Cates, George A., Richmond Hill, Canada  
Ewasyshyn, Mary E., Willowdale, Canada  
PA Virogeneitics Corporation, Troy, NY, United States (U.S. corporation)  
Connaught Laboratories Limited, North York, Canada (non-U.S.  
corporation)  
PI US 6180398 B1 20010130  
AI US 1996-679065 19960712 (8)  
DT Utility  
FS Granted  
LN.CNT 1233  
INCL INCLM: 435/320.100  
INCLS: 435/235.100; 435/069.100; 435/069.300; 424/232.100; 424/199.100  
NCL NCLM: 435/320.100  
NCLS: 424/199.100; 424/232.100; 435/069.100; 435/069.300; 435/235.100  
IC [7]  
ICM: C12N015-00  
ICS: A61K039-275; A61K039-12  
EXF 424/184.1; 424/204.1; 424/211.1; 424/93.2; 424/232.1; 424/199.1; 435/5;  
435/69.1; 435/69.3; 435/235.1; 435/237; 435/172.3; 435/320.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 3 OF 10 USPATFULL  
AN 2001:1631 USPATFULL  
TI Methods for making modified recombinant vesiculoviruses

IN Rose, John K., Guilford, CT, United States  
PA Yale University, New Haven, CT, United States (U.S. corporation)  
PI US 6168943 B1 20010102  
AI US 1996-646695 19960503 (8)  
RLI Continuation-in-part of Ser. No. US 1995-435032, filed on 4 May 1995  
DT Utility  
FS Granted  
LN.CNT 2933  
INCL INCLM: 435/239.000  
INCLS: 424/199.100; 424/224.100; 424/093.210; 435/235.100; 435/325.000;  
435/320.100; 514/044.000; 536/023.720  
NCL NCLM: 435/239.000  
NCLS: 424/093.210; 424/199.100; 424/224.100; 435/235.100; 435/320.100;  
435/325.000; 514/044.000; 536/023.720  
IC [7]  
ICM: A61K039-205  
ICS: C07H021-04; C07K014-145; C12N007-01  
EXF 435/235; 435/235.1; 435/239; 435/325; 435/320.1; 424/199.1; 424/224.1;  
424/93.21; 514/44; 536/23.72  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 4 OF 10 USPATFULL  
AN 2000:174402 USPATFULL  
TI Parainfluenza virus glycoproteins and vaccines  
IN Cates, George A., Richmond Hill, Canada  
Ewasysbyn, Mary E., Willowdale, Canada  
Fahim, Raafat E. F., Mississauga, Canada  
Jackson, Gail E. D., Richmond Hill, Canada  
Klein, Michel H., Willowdale, Canada  
Symington, Alison L., Toronto, Canada  
PA Connaught Laboratories Limited, Toronto, Canada (non-U.S. corporation)  
PI US 6165774 20001226  
WO 9711093 19970327  
AI US 1998-43477 19980808 (9)  
WO 1996-CA639 19960923  
19980807 PCT 371 date  
19980807 PCT 102(e) date  
DT Utility  
FS Granted  
LN.CNT 1695  
INCL INCLM: 435/238.000  
NCL NCLM: 435/238.000  
IC [7]  
ICM: C12N007-06  
EXF 435/238  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 5 OF 10 USPATFULL  
AN 2000:87721 USPATFULL  
TI Bovine adenovirus expression vector system  
IN Mittal, Suresh K., Saskatoon, Canada  
Graham, Frank L., Hamilton, Canada  
Prevec, Ludvik, Burlington, Canada  
Babiuk, Lorne A., Saskatoon, Canada  
PA University of Saskatchewan, Saskatoon, Canada (non-U.S. corporation)  
PI US 6086890 20000711  
AI US 1997-815927 19970313 (8)  
RLI Continuation of Ser. No. US 1993-164292, filed on 9 Dec 1993, now  
patented, Pat. No. US 5820868  
DT Utility  
FS Granted  
LN.CNT 3639  
INCL INCLM: 424/199.100

INCLS: 424/205.100; 424/233.100; 424/093.200; 435/235.100; 435/320.100  
NCL NCLM: 424/199.100  
NCLS: 424/093.200; 424/205.100; 424/233.100; 435/235.100; 435/320.100  
IC [7]  
ICM: A61K039-235  
ICS: C12N007-01; C12N015-86  
EXF 424/199.1; 424/205.1; 424/233.1; 424/93.2; 435/320.1; 435/235.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 6 OF 10 USPATFULL  
AN 2000:57602 USPATFULL  
TI RNA respiratory syncytial virus vaccines  
IN Parrington, Mark, Bradford, Canada  
PA Connaught Laboratories Limited, North York, Canada (non-U.S. corporation)  
PI US 6060308 20000509  
AI US 1997-923558 19970904 (8)  
DT Utility  
FS Granted  
LN.CNT 1079  
INCL INCLM: 435/320.100  
INCLS: 435/069.300; 424/186.100; 424/199.100; 424/204.100; 424/211.100;  
424/218.100; 424/093.600; 514/044.000  
NCL NCLM: 435/320.100  
NCLS: 424/093.600; 424/186.100; 424/199.100; 424/204.100; 424/211.100;  
424/218.100; 435/069.300; 514/044.000  
IC [7]  
ICM: C12N015-45  
EXF 435/320.1; 435/69.3; 424/186.1; 424/199.1; 424/204.1; 424/211.1;  
424/218.1; 424/93.6; 514/44  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 7 OF 10 USPATFULL  
AN 1999:163447 USPATFULL  
TI Recombinant bovine adenoviruses  
IN Mittal, Suresh K., Saskatoon, Canada  
Graham, Frank L., Hamilton, Canada  
Prevec, Ludvik, Burlington, Canada  
Babiuk, Lorne A., Saskatoon, Canada  
PA University of Saskatchewan, Saskatoon, Canada (non-U.S. corporation)  
PI US 6001591 19991214  
AI US 1997-845623 19970425 (8)  
RLI Division of Ser. No. US 1993-164292, filed on 9 Dec 1993, now patented,  
Pat. No. US 5820868  
DT Utility  
FS Granted  
LN.CNT 3969  
INCL INCLM: 435/069.100  
INCLS: 435/235.100; 435/320.100; 424/199.100  
NCL NCLM: 435/069.100  
NCLS: 424/199.100; 435/235.100; 435/320.100  
IC [6]  
ICM: C12N015-00  
ICS: C12N007-01; C12N015-86  
EXF 424/93.2; 424/199.1; 514/44; 435/235.1; 435/320.1; 435/69.1  
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

d 14 1-2 all

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2002 ACS  
AN 2001:713077 CAPLUS  
DN 135:270010  
TI Recombinant parainfluenza virus expression systems and vaccines  
IN Haller, Aurelia; Coelingh, Kathleen L.  
PA Aviron, USA  
SO PCT Int. Appl., 60 pp.  
CODEN: PIXXD2  
DT Patent  
LA English  
IC ICM A01N063-00  
ICS A61K039-155  
CC 10-4 (Microbial, Algal, and Fungal Biochemistry)  
Section cross-reference(s): 3, 15

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001070032	A1	20010927	WO 2001-US9091	20010321
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,				
	CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,				
	HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,				
	LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,				
	RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ,				
	VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,				
	DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,				
	BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				

PRAI US 2000-531375 A 20000321

AB The present invention relates to recombinant bovine parainfluenza virus 3 (bPIV) cDNA or RNA which may be used to express heterologous gene products in appropriate host cell systems and/or to rescue neg. strand RNA recombinant viruses that express, package, and/or present the heterologous gene product. The heterologous sequences encoding F and HN glycoproteins or G protein of human parainfluenza virus, influenza virus or respiratory syncytial virus interchange with those of bPIV3 to make **chimeric** bovine PIV virus. In addn. to heterologous sequence, the polymerase (L) gene of bovine parainfluenza virus 3 also has a mutation at position 1103, resulting in a temp.-sensitive phenotype. The **chimeric** bovine PIV virus shows attenuated phenotype and elicit strong protective response when administered in vivo. The **chimeric** viruses and expression products may advantageously be used in vaccine formulations including vaccines against a broad range of pathogens and antigens.

ST recombinant parainfluenza virus vaccine

IT Proteins, specific or class

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(F, gene for; recombinant parainfluenza virus expression systems and vaccines, genes in bovine parainfluenza virus 3 genome substituted by heterologous sequence from other viruses)

IT Gene, microbial

RL: BUU (Biological use, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(F; recombinant parainfluenza virus expression systems and vaccines, genes in bovine parainfluenza virus 3 genome substituted by heterologous sequence from other viruses)

IT Gene, microbial